Cell Expansion Market Overview:
The global cell expansion market was valued at $13,066.2 million in 2020, and is projected to reach $39,031.1 million by 2030, registering a CAGR of 11.6% from 2021 to 2030.
Cell expansion is the process of producing daughter cells from a single cell. Cell expansion requires the synthesis of new cell wall material and controlled loosening of the wall to allow it to stretch and increase in area. Cell-wall-associated proteins of the so-called expansion family are key components in this process. It is utilized in drug development, drug screening, and cell microbiology research. Cell expansion is now frequently utilized to improve transplantation and the treatment of diseases, including rheumatoid arthritis and diabetes.
The growth in incidences of chronic diseases such as diabetes, rheumatoid arthritis, and cancer is key factor that drives the growth of the global cell expansion market. In addition, rise in government investments for cell-based research and increase in focus on R&D for cell-based therapies further drive the growth of the market. However, ethical concerns regarding research in cell biology, shortage of skilled professionals, and high cost of cell-based therapies may hamper the growth of the cell expansion market. On the contrary, growth in opportunity in emerging markets and rise in focus on personalized medicine create lucrative opportunities for the cell expansion market.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. However, there has also been a positive effect and surge in demand for various medical services, including cell expansion. Cell-based approaches, primarily using mesenchymal stromal cells (MSCs), offers a promising approach toward mitigating the adverse effects of the COVID-19 infection. This therapy has shown to reduce the expression of pro-inflammatory cytokines as well as repair of damaged tissues in COVID-19 patients. According to the WHO ICTRP and the NIH ClinicalTrials.gov databases, 27 clinical investigations of MSC-based cell therapy approaches have begun in China since the onset of the COVID-19 outbreak, as well as a growing number of academic and industry trials elsewhere. Regenerative medicine & stem cell research is one of the major applications of cell expansion. This is a major indicator of market growth as stem cell-based therapies are showing significant potential in COVID-19 study. In addition, various cell expansion products (such as cell culture media) and instruments (such as bioreactors) are being used in COVID-19 research. Hence, the outbreak of COVID-19 has positively impacted the cell expansion market.
Cell Expansion Market Segmentation
The global cell expansion market is segmented on the basis of product, application, end user, and region. By product, the market is bifurcated into instruments and consumables. By application, the market is divided into stem cell technology, cancer research, drug screening & development, tissue engineering & regenerative medicine, and others. Others again classified into clinical studies and toxicology studies. By end user, it is classified into research institutes, pharmaceutical & biotechnology companies, and others. Others is again segmented into CROs, forensic, and diagnostic laboratories. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Based on product, the market is segmented into consumable and instrument. The consumables segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to increase in production of vaccines and other biologics in the biopharmaceutical and biotechnology industries.
Consumables segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
Based on application, the market is segmented into stem cell technology, cancer research, drug screening & development, tissue engineering & regenerative medicine, and others. The tissue engineering & regenerative medicine segment is expected to be the second largest during the forecast period, owing to recent advancements in regenerative medicine and tissue engineering and increased funding for regenerative medicine.
Tissue Engineering & Regenerative Medicine segment is projected as one of the most lucrative segment.
Based on end user, the market is divided into research institutes, pharmaceutical & biotechnology companies, and others. Pharmaceutical & biotechnology companies held the largest market share in 2020, and is expected to remain dominant throughout the forecast period, owing to broadening horizon of cell-based therapeutics in the healthcare industry, high burden of chronic diseases, and increase in R&D activities in the pharmaceutical and biotechnology industries.
Snapshot of the Asia-Pacific cell expansion market
Asia-Pacific is expected to exhibit the fastest market growth during the forecast period, owing to constantly expanding healthcare infrastructure and economic development. In addition, Asia-Pacific offers profitable opportunities for key players operating in the cell expansion market; thereby, registering the fastest growth rate during the forecast period, mainly due to economic development and low operating costs.
North America is expected to experience growth at the highest rate, registering a CAGR of 11.20 % during the forecast period.
The major driving factors for the market growth in this region include rise in focus in biopharmaceutical R&D, huge production of drugs, and surge in prevalence of cancer. In addition, increasing efforts laid down by several local pharmaceutical and biotechnology companies to develop and commercialize their cellular therapies further boost the market growth. For instance, an Indian company, Stempeutics Research Pvt. Ltd., signed an alliance with Kemwell Biopharma in July 2019 for the commercialization of its stem cell-based product, Stempeucel. Such agreements are expected to boost the product sales of small- and mid-scale companies.
The key market players profiled in the report include Becton, Dickinson and Company, Corning Incorporated, Eppendorf, Sartorius AG, Merck KGaA, Lonza Group AG, PromoCell GmbH, Danaher Corporation, Thermo Fisher Scientific, and HiMedia Laboratories.
Key Benefits For Stakeholders
- The study provides an in-depth analysis of the global cell expansion market along with the current trends and future estimations to explain the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the cell expansion market growth is provided in the report.
- Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the key segments of the industry helps to understand the application and products of cell expansion used across the globe.
- Key market players and their strategies have been analyzed to understand the competitive outlook of the cell expansion market.
Key Market Segments
- Stem Cell Technology
- Cancer Research
- Drug Screening and Development
- Tissue Engineering & Regenerative Medicine
By End User
- Research Institutes
- Pharmaceutical & Biotechnology Companies
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- South Africa
- Rest of LAMEA
Cell Expansion Market Report Highlights
By END USER
Key Market Players
PromoCell GmbH, Lonza Group Ltd, DANAHER CORPORATION, Becton, Dickinson, and Company, THERMO FISHER SCIENTIFIC, INC., HIMEDIA LABORATORIES, SARTORIUS AG, CORNING GROUP, INC., EPPENDORF CORPORATE, Merck KGAA
Cell expansion is the large-scale artificial generation of daughter cells from a single cell. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies.
Increase in prevalence of chronic diseases, surge in government support and investment for cell-based therapies, and rise in focus on R&D for cell-based therapies are expected to drive the growth of the cell expansion market. Furthermore, growing opportunities in emerging economies and increase in focus on personalized medicine also create a lucrative opportunity for the market growth. However, high cost of cell-based research and their treatment and shortage of skilled professionals and ethical concerns regarding research in cell biology are expected to hinder the growth of the market.
The consumable segment is expected to remain dominant during the forecast period, owing to increase in production of vaccines and other biologics in the biopharmaceutical and biotechnology industries. Moreover, North America is expected to offer lucrative opportunities to the key players during the forecast period, due to rise in incidences of cancer, increase in government funding, rise in research activates on stem cell therapies, and growth in awareness regarding advanced treatment methods.